DEZAWA MARI has a total of 24 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2005. It filed its patents most often in United States, Republic of Korea and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are VCELL THERAPEUTICS INC, GUNTAKA RAMAREDDY V and OMNICYTE LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | Republic of Korea | 4 | |
#3 | Australia | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | Hungary | 1 | |
#8 | Singapore | 1 | |
#9 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Dezawa Mari | 24 |
#2 | Fujiyoshi Yoshinori | 17 |
#3 | Nabeshima Youichi | 17 |
#4 | Wakao Shohei | 16 |
#5 | Sawada Hajime | 2 |
#6 | Mori Keita | 2 |
#7 | Kuroda Satoshi | 2 |
#8 | Takano Masahiko | 2 |
#9 | Yoshida Masanori | 2 |
#10 | Kuroda Yasumasa | 2 |
Publication | Filing date | Title |
---|---|---|
US2012244129A1 | SSEA3(+) pluripotent stem cell that can be isolated from body tissue | |
US2011070647A1 | SSEA-3 pluripotent stem cell isolated from body tissue |